These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27203487)

  • 21. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF; Singh D; Munzu C; Kilbride S; Church A
    Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.
    Adamson PD; Anderson JA; Brook RD; Calverley PMA; Celli BR; Cowans NJ; Crim C; Dixon IJ; Martinez FJ; Newby DE; Vestbo J; Yates JC; Mills NL
    J Am Coll Cardiol; 2018 Sep; 72(10):1126-1137. PubMed ID: 30165984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R; Norris V; Siederer S
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
    Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
    Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Umeclidinium-vilanterol inhaler approved for COPD.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(3):174. PubMed ID: 24429003
    [No Abstract]   [Full Text] [Related]  

  • 29. Vilanterol trifenatate for the treatment of COPD.
    Malerba M; Radaeli A; Montuschi P; Morjaria JB
    Expert Rev Respir Med; 2016 Jul; 10(7):719-31. PubMed ID: 27143334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
    Stanbrook MB
    Ann Intern Med; 2015 Dec; 163(12):JC10. PubMed ID: 26666800
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rogliani P; Rinaldi B; Cazzola M
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):35-41. PubMed ID: 25382021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium.
    Hussar DA; Ahmad A
    J Am Pharm Assoc (2003); 2013; 53(6):662-70. PubMed ID: 24185435
    [No Abstract]   [Full Text] [Related]  

  • 35. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J
    Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
    Davidson JF; Donohue JF; Ohar JA
    Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ; Neffen H
    Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.